One Instrument, One Patient at a Time

LivaNova Names ECA Medical Instruments 2017 Supplier of the Year Award Winner

Cited for providing quality and sustained value delivering precision single-procedure torque-limiting instruments for LivaNova’s cardiac rhythm management and neuromodulation products

 
Thousand Oaks, CA – ECA Medical Instruments, the leading global designer and manufacturer of single-procedure torque-limiting instruments and procedural kits for the medical industry, was named LivaNova 2017 Supplier of the Year Award winner. ECA was one of just 3 strategic partner firms out of 300 LivaNova suppliers worldwide to win the prestigious award.

“We have the pleasure to recognize ECA Medical Instruments as the LivaNova 2017 Supplier of the Year,” said Pascal Chaussepied, Purchasing Director, CRM and Neuro. “This award honors ECA’s overall performance in areas including quality, logistics, cost and customer service and support. Supplier performance is fundamental to LivaNova’s success to remain competitive within the challenging CRM market and global environment. We congratulate the ECA team and its management for the continuous outstanding level of performance,” he said.

ECA designs and manufactures a variety of precision single-use torque-limiting instruments used by surgeons to secure delicate electrodes and leads that connect LivaNova pacemakers and defibrillators to the heart. ECA’s instruments also secure electrodes to LivaNova’s Vagus Nerve neuromodulation devices used to treat people affected by treatment-resistant epilepsy, depression, heart failure and other disorders. ECA’s instruments are single-use meaning a pristine instrument is used for each mission critical implant and for each patient.

“This is a tremendous honor for ECA and our global team of medical device employees, who are dedicated to providing LivaNova with pristine single-procedure instrumentation. ECA has been successfully supporting LivaNova across multiple life sustaining product lines for many years,” said Lane Hale, President and CEO of ECA Medical Instruments.

“Winning the LivaNova 2017 Supplier of the Year Award underscores our commitment to providing single-procedure instrumentation that offers clinical and economic value. We are always striving with our customers and partners to jointly improve the quality of people’s lives—one instrument, one patient at a time,” he said.

Single-procedure torque-limiting instruments and procedural kits provide surgeons and patients alike with a pristine set of surgery ready instruments for addressing a wide range of procedures. Sustained benefits include elimination of reprocessing costs, improved OR efficiency, reduced risk of surgical site infection, and reduction in hospital and outpatient surgery center inventory management.

ECA is a one-stop shop OEM instrument company providing medical device implant firms with complete product design and development, product and packaging validations, CE Mark and dock to stock operations. This reduces OEM costs and accelerates time to market.

About ECA Medical Instruments
ECA Medical Instruments®, headquartered in Thousand Oaks, CA., is the industry leader in designing and manufacturing precision single-procedure torque-limiting instruments and surgical fixation kits. Founded in 1979, the company has delivered over 35 million torque-limiting instruments and procedural kits to the world’s leading cardio, neuromodulation, orthopaedic and spine implant companies. Every 15 seconds of every day an ECA torque instrument or procedural kit is used to secure a medical implant—One Instrument, One Patient at a Time™. ECA, a LongueVue Capital Partners company, is an ISO 13485, CE Mark certified and FDA registered firm and was named Business of the Year 2017 by LivaNova and earned the LivaNova 2017 Supplier Excellence Award. www.ecamedical.yourpixelpusher.com

About LivaNova
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs more than 4,500 employees. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

For more information, please visit www.livanova.com.